



PRISMA 2020 Checklist (Partial only)

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	n.a.
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	n.a.
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	The growing availability of high-quality medical data and advanced computing power made digital twins more accessible and accurate, driving their widespread adoption. Since the 2020s, AI-based DTs in healthcare have been poised to revolutionize patient care, offering unprecedented levels of personalization and predictive power.
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	RQ1: evolution of research topics/problems over time, RQ2: geographical distribution of studies/publications, authors, scientific institutions and publications with the highest impact, and RQ3: topics that may shape future research programs.
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Criteria for inclusion of articles in the review: English-language original and review articles, also full-text conference articles and chapters in books, open source, indexed by major bibliometric databases: WOS, Scopus, PubMed. Criteria for exclusion from the review: languages other than English, other forms of publication (reports, abstracts, etc.), no full text available Open Source.
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Web of Science, Scopus, PubMed
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Article Fig 3.
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Article Fig. 4
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	After analyzing the content of the main databases in the area of AI-based DTs, we searched for research articles in three main databases: WoS, Scopus, and PubMed. This choice was dictated by the wide scope of research results contained in them and the detailed data and analytical tools enabling comprehensive analyses, which is especially beneficial when conducting interdisciplinary bibliometric analyses and assessing the impact of research results, as was the case in ours. When creating advanced queries tailored to our research goals, we applied filters to select relevant publications. In this way, we limited our search to articles in English. Later in the study, we manually



PRISMA 2020 Checklist (Partial only)

Section and Topic	Item #	Checklist item	Location where item is reported
			reviewed the articles again, excluding some of them (including duplicate articles) to match our research goals, which resulted in the final sample size (Figure 4). The WoS search was performed using "Topic" (search using the set: title, abstract, keyword plus and other keywords), the Scopus search was performed using the set: article title, abstract, keywords, and the PubMed search was performed using manual keyword sets. Three databases were searched using the keywords "artificial intelligence" or "machine learning", "digital twin" and "healthcare". The obtained publications were subjected to further selection (Figure 4).
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	n.a.
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	n.a.
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	n.a.
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	n.a.
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	Article Figure 5 Article Table 1
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	n.a.
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	n.a.
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	n.a.
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	n.a.
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	n.a.
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	n.a.
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	n.a.
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified	n.a.



PRISMA 2020 Checklist (Partial only)

Section and Topic	Item #	Checklist item	Location where item is reported
		in the search to the number of studies included in the review, ideally using a flow diagram.	
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	n.a.
Study characteristics	17	Cite each included study and present its characteristics.	n.a.
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	n.a.
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	n.a.
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	n.a.
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Article, results section
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	n.a.
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	n.a.
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	n.a.
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	n.a.
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Article Discussion section
	23b	Discuss any limitations of the evidence included in the review.	n.a.
	23c	Discuss any limitations of the review processes used.	n.a.
	23d	Discuss implications of the results for practice, policy, and future research.	n.a.
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	n.a.
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	n.a.
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	n.a.
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	n.a.
Competing interests	26	Declare any competing interests of review authors.	n.a.
Availability of data, code and	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code;	n.a.



PRISMA 2020 Checklist (Partial only)

Section and Topic	Item #	Checklist item	Location where item is reported
other materials		any other materials used in the review.	

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.doi: 10.1136/bmj.n71